{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q6UVK1",
      "entity_text" : "CSPG4",
      "entity_type" : "gene"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0614" ],
      "CellType" : [ "cl:CL:0000084" ]
    }
  },
  "verbose_text" : "The approximately 50% success rate observed in these inceptive clinical studies has incited a more extended Phase II trial performed at CRO National Cancer Institute Aviano (Italy) on over 100 advanced melanoma patients who were selected for the high NG2 / CSPG4 expression in the primary lesions and lack of brain metastases.",
  "reading_complete" : "2020-08-02T18:42:17Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T18:39:19Z",
  "trigger" : "expression",
  "evidence" : [ "CSPG4 expression" ],
  "pmc_id" : "4350014",
  "score" : 0
}